Recent studies have investigated CAR-T cells targeting IL13Rα2 that were delivered intracranially into the resection cavity of three patients with recurrent GBM, demonstrating good tolerance and manageable transient encephalitis. This evidence concerns the gene IL13RA2 and glioblastoma.